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Introduction: Lung cancer survival in Scotland has historically
been poor but many changes to the lung cancer services have been
introduced and this study was conducted to investigate the impact of
these changes on treatment and survival.
Methods: Data obtained from the Scottish Cancer Registry, South-
East Scotland Cancer Network audit and Edinburgh Cancer Centre
database were used to conduct a comparison of the management and
outcomes of lung cancer patients from South-East Scotland diag-
nosed in 1995 and in 2002.
Results: Data on 971 patients diagnosed in 2002 and 927 in 1995
were analyzed and demonstrated that though the use of treatment
overall had not changed (62% in 2002 versus 63% in 1995) the use
of potentially curative radiotherapy (15 versus 5% 2 p 0.001) and
chemotherapy for non-small cell lung cancer (18 versus 7% 2 p 
0.001) had increased, but not resection rates (11 versus 10%). The
use of palliative radiotherapy declined (38% versus 31% 2 p 
0.001). Patients diagnosed in 2002 had an adjusted hazard of death
of 0.7 (95% confidence interval, 0.6–0.8) compared with 1995, with
median survival from date of diagnosis of 5.2 versus 4.1 month and
2 year overall survival 15 versus 11% (log rank p  0.004).
Localized disease and younger age were also associated with a
reduced hazard of death.
Conclusions: Patients diagnosed with lung cancer in Scotland in
2002 had a reduced hazard of death and improved survival com-
pared with 1995. It is hypothesized that this was due in part to
improvements in service organization and increased use of treat-
ments likely to increase survival.
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Although there have been sizeable improvements in theoutcome of patients with many cancers,1 population-
based survival after a diagnosis of lung cancer has changed
little over the last 20 years, and remains unacceptably low.1–3
The results of a Scottish national audit of lung cancer
patients diagnosed in 1995 have been previously published,4–6
and demonstrated poor outcome with a median survival of 3.6
months for all Scottish patients. Since 1995, there have been
a number of changes to healthcare organization and the staff
treating lung cancer in South-East Scotland, which have
included:
1. The introduction of a managed clinical network
(South-East Scotland Cancer Network or SCAN) to
ensure smoother referral pathways and better patient
management.
2. The introduction of national patient management guide-
lines through the Scottish Intercollegiate Guidelines
Network. The first lung cancer guidelines were pub-
lished in 1998 and revised in 2005.
3. The introduction of multidisciplinary team meetings at
which all newly diagnosed patients are discussed.
4. Appointment of more oncologists specializing in lung
cancer; the number increased from 2 in 1995 to 4 in
2002. Consequently, all patients should have the oppor-
tunity to benefit from the opinion of a specialist respi-
ratory oncologist.
Other changes in clinical practice have also occurred,
primarily:
1. Greater access to computed tomography (CT) scanning
and the development of scanners with improved image
quality.
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2. Increasing evidence supporting the use of chemotherapy in
stage III and IV non-small cell lung cancer (NSCLC).
3. Increasing evidence on the use of chemo-radiation in
limited stage SCLC.
4. More experience with 3D-conformal radiotherapy, so
patients with large tumors or poor pulmonary function
are now offered this treatment.
Therefore the question is, have these changes resulted
in an improvement in treatment and survival of lung cancer
patients in South-East Scotland? This study was conducted to
compare the original 1995 cohort with a group of patients
diagnosed in 2002 to assess the impact of these changes on
treatment and the median, 1- and 2-year survival.
METHODS AND MATERIALS
SCAN covers a population of 1.4 million in the 4
Scottish healthboard regions of Lothian, Borders, Fife, and
Dumfries & Galloway. All radiotherapy is delivered at the
Edinburgh Cancer Centre (ECC), which in 1995 had four, and
in 2002, five linear accelerators. The majority of chemother-
apy is delivered under the supervision of an oncologist, but in
2002 respiratory physicians still administered some chemo-
therapy. Lung cancer surgery is performed in the Royal
Infirmary in Edinburgh, but patients living in Dumfries and
Galloway usually have their surgery performed in Glasgow.
Therefore, for this study only patients living in Lothian,
Borders and Fife were included (population 1.2 million).
Data Sources
Integral to the development of the cancer networks has
been the introduction of prospective audit. Cases are identi-
fied through the multidisciplinary team meetings, pathology
reports, the ECC database, and the Scottish Cancer Registry.
Data on patient characteristics including date of birth, sex,
address, and performance status are collected. Tumor details
are recorded, including how the diagnosis was made, staging
investigations, pathologic type, and stage. Staging is recorded
where possible according to the 1997 UICC TNM system.
However, in the 1995 audit only “local,” “regional,” or
“metastatic” stages were recorded so this was also noted for
the 2002 patients.
Since 1995, the allocation of deprivation by postcode
across Scotland has altered as some areas have become more
affluent and others less so. Consequently, it is recommended
that the Carstairs index based on the 2001 census is used in
longitudinal studies.7 Therefore, both the 1995 and 2002
cohorts were linked to the 2001 Carstairs Index.
Since 1974, the ECC has had a computerized database
that includes data on all referred patients and includes details
of all radiotherapy and chemotherapy treatments delivered
under the supervision of the oncologists and tracks each
patient’s survival until death.
Firstly, patients residing in Lothian, Borders and Fife
healthboard areas diagnosed with lung cancer in 2002 were
identified from the SCAN and the ECC databases. Then
pharmacy records from all the hospitals were checked to
ensure all chemotherapy episodes had been identified. The
hard-copy records of all thoracic operations were hand-
searched and details of all lung cancer resections recorded.
Once a final list of patients managed under the care of
the SCAN lung cancer team had been prepared, the database
was then given to the Scottish Cancer Registry to identify any
missing cases. Details of the patients who had not been
identified by the audit, but had died were supplied to the
research staff to check the medical records, but for those still
alive only name, date of birth and contact details of their
general practitioner (GP) were supplied. A condition of the
ethical approval for this study was that these patients were
required to give consent before the release of more detailed
information.
The medical records of the additional cases were scruti-
nized to assess if they were eligible for entry into the audit and
patient, tumor and management details recorded. For those
patients whose hospital medical records could not be located,
additional letters were sent to their GP to ask for further details.
The details of all cancer therapies delivered within 6
months of diagnosis were recorded. An exception was made
for consolidation radiotherapy after chemotherapy in limited
stage SCLC as this is part of the “initial treatment package,”
but can commence during the seventh month after diagnosis.
Treatment intent was defined as potentially curative
therapy (PCT) if the patient had undergone either surgery,
radical radiotherapy with a dose of 50 Gy, or for limited
stage small-cell lung cancer chemo-radiation with thoracic
radiotherapy with a dose of 30 Gy. These definitions were
identical to those used in the 1995 audit.
To obtain up-to-date survival, the records of the Gen-
eral Register Office of Scotland were searched for notification
of any patient deaths.
Once the database for 2002 patients was finalized, com-
parison was then made with the patients in the 1995 audit from
Lothian, Borders and Fife. The details on the methods of data
collection of the 1995 audit are set out elsewhere.6 The 1995
audit excluded patients with a death certificate only diagnosis
and those whose medical records could not be located.
The Multi-Centre Ethics Research Committee for Scot-
land granted ethical approval for this study.
Analysis
Patient, tumor, and management characteristics were
analyzed using descriptive statistics and compared using
either 2 for categorical or analysis of variance for continuous
variables. Factors affecting the probability of use of treatment
were examined using logistic regression models. Survival
from time of diagnosis (pathologic confirmation or if not
obtained, radiologic diagnosis) till death or last follow-up
was estimated using the Kaplan Meier method and compared
using log-rank tests and Cox’s regression models.
RESULTS
In 2002, a total of 878 patients were identified by the
SCAN audit and the Scottish Cancer Registry identified an
additional possible 149 cases of which 106 were verified after
location of their medical records. For the remaining 43 cases
identified by the Cancer Registry, neither the hospital nor GP
medical records could be located (unverified cases). Only two
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of the unverified patients had not been under the care of a
member of SCAN lung cancer team and were still alive.
Neither patient could be contacted for permission to access
their records so they were excluded. Therefore a total 984
verified cases and 43 unverified cases were identified.
Of the 3833 patients in the 1995 Scottish lung cancer
audit, 927 were from Lothian, Borders or Fife. The propor-
tion of cases in the Scottish Cancer Registry from the three
health boards that were included the audit was much higher in
the 2002 (94%) than in 1995 (86%).
Patient and Tumor Characteristics
In the 2002 cohort, there were no significant differences
in the patient characteristics of the verified and unverified
patients. Only 11 (26%) of the unverified cases had patho-
logic confirmation (recorded in cancer registry) compared
with 716 (73%) the verified cases. Of the other verified cases,
eight were confirmed at postmortem and 260 were diagnosed
on radiology alone. In 86 (33%) of the radiologic-only diag-
nosis cases a biopsy had been performed, but was nondiag-
nostic. Thirteen cases were either confirmed at autopsy or
died on the day they were diagnosed (3 SCLC, 8 NSCLC, and
2 radiologic), and as these patients would have been unable to
receive any treatment they have been excluded from the
analysis of management.
To investigate the impact of the improved case ascer-
tainment, the Scottish Cancer Registry also provided data on
the eligible cases from the 1995 audit that had been excluded
because the medical records could not be located. There were
67 patients, of whom 39 were male and the median age was
75 (range, 34–92), over half this group (58%) died on the day
they were diagnosed. There were no differences between the
sex or age distribution of the 67 patients excluded from 1995
and the 56 excluded from the 2002 cohort.
The patient and tumor characteristics of the remaining
971 patients diagnosed in 2002 and of the 927 patients
diagnosed in 1995 are shown in Table 1. Performance status
was not collected in the 1995 audit.
A significantly higher proportion of patients underwent
a staging CT scan in 2002 (85% versus 46% 2 p  0.001).
This may explain the apparently lower proportion of patients
diagnosed with localized disease in 2002 (14% versus 25%)
and higher proportion of patients with metastatic disease
(42% versus 30%).
The median follow-up of the patients diagnosed in 2002
who were still alive was 40 months (range, 0.3–55).
Management
No record could be found of any of the unverified cases
from 2002 receiving any treatment for their lung cancer. On
review of the medical records of the 106 patients identified
only by the Cancer Registry none were felt to have been
suitable for PCT. This group constituted mainly patients
admitted under the care of Medicine for the Elderly and who
died within a few days of entering hospital.
Details of the treatment delivered in 1995 and 2002 are
shown in Table 2 . The overall proportion of patients receiv-
ing treatment did not increase in the 7 years; in 1995 63%
received some form of treatment compared with 62% in
2002. Nevertheless, the proportion of patients treated with
curative intent increased from 14% to 24% (2 p  0.001),
primarily because of a trebling of the number of people
treated with potentially curative radiotherapy (5% versus
15% 2 p  0.001) The proportion of patients treated with
radiotherapy overall did not change (45% versus 43%), how-
ever, those treated were more likely to have received a
potentially curative dose.
Disappointingly there was no increase in the proportion
under-going surgery for their lung cancer (10.2% versus
10.5% of all cases and 17.6% versus 16.8% NSCLC).
The number of patients receiving chemotherapy in-
creased, mainly because of doubling of the use of chemother-
apy in NSCLC (7% versus 18% 2 p  0.001). The propor-
tion of SCLC patients receiving chemotherapy did not
change, and was 65% in 1995, and 68% in 2002 (2 p 0.7).
To investigate further, the factors that affected the use
of “any treatment” and “PCT” a logistic regression analysis
was performed (Table 3). The adjusted odds of receiving any
treatment in 2002 was 1.3 (1.1–1.7) compared with 1995, and
TABLE 1. Patient and Tumor Characteristics in 1995 and
2002 Cohorts
1995 (n  927) 2002 (n  984) p
Sex, male 538 (58%) 537 (55%) 0.25
Age
60 135 (15%) 131 (14%) 0.002a
60–69 298 (32%) 246 (25%)
70–79 359 (39%) 411 (42%)
80 135 (15%) 183 (19%)
PFS





1 131 (14%) 149 (15%) 0.13
2 155 (17%) 175 (18%)
3 240 (26%) 217 (22%)
4 258 (28%) 316 (33%)
5 120 (13%)b 114 (12%)
Lothian 682 (74%) 605 (62%) 0.001
Borders 53 (6%) 89 (9%)
Fife 192 (21%) 277 (29%)
Pathology
NSCLC 543 (59%) 572 (59%) 0.055
SCLC 166 (18%) 141 (15%)
No pathology 216 (23%) 258 (27%)
Localized 229 (25%) 132 (14%) 0.001
Regional 314 (34%) 339 (35%)
Metastatic 275 (30%) 411 (42%)
Unknown 109 (12%) 89 (9%)
CT scan performed 430 (46%) 822 (85%) 0.001
a ANOVA p  0.001.
b For 23 data missing.
PFS, performance status; NSCLC, non-small cell lung cancer; SCLC, small cell
lung cancer.
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6.0 (4.3–8.4) for PCT. Older patients, those with more
advanced disease and patients from Fife were less likely to
receive both “any treatment” and “PCT.” The lower rates in
Fife were primarily due to fewer patients having radiother-
apy, particularly with radical intent (in 2002 radical RT: 18%
Lothian, 21% Borders, 8% Fife 2 p  0.001).
Survival
The median overall survival for lung cancer patients in
South-East Scotland increased from 4.1 month to 5.2 months
in the 7 years from 1995 to 2002, and the overall survival at
2 years increased from 11% to 15%, and at 3 years from 8.0%
to 11.5% (log rank p  0.004) (Table 4 and Figure 1). For
those patients who had pathologic confirmation (comparable
to SEER data8) the median survival was 5.4 (4.5–6.2) months
in 1995 and 5.9 (5.1–6.7) months in 2002, with 14% and
17.5% alive at 2-years and 10% and 12.5% alive at 3 years,
in 1995 and 2002, respectively (log rank p  0.043).
For the whole population cohort of 994 patients (927
67 excluded) diagnosed in 1995 and 1027 (971  56 ex-
cluded) patients from 2002, the median survival in 1995 was
3.6 (3.1–4.1) months and 4.8 (4.2–5.3) months in 2002, with
11% and 14% alive at 2 years and 8% and 10% at 3 years,
respectively (log rank p  0.001).
Reasons for the Improvement in Survival
To explore whether the improvement in survival ob-
served was simply due to changes in patient and tumor
characteristics, rather than the impact of increased use of
treatment, a Cox’s regression model analysis was performed.
This demonstrated that even when the differences in age and
stage were taken into account, patients diagnosed in 2002 had
an adjusted hazard of death of 0.7 (0.6–0.8) compared with
patients diagnosed in 1995. Localized disease, younger age,
and pathologic confirmation were the only other factors
associated with a reduced hazard of death.
When the model was repeated with the addition of the
variable “treatment intent” (PCT versus palliative versus
none) the hazard of death was still lower in 2002 compared
with 1995 (hazard ratio 0.8; range, 0.7–0.9) suggesting that it
was not just the increased use of PCT that was responsible for
the improved outcome.
There was no change in the overall survival after
surgery (2-year overall survival 77% versus 81%, 3-year 58%
versus 54%, in 1995 and 2002 respectively, log rank p 
0.94), radical radiotherapy (2-year overall survival 25% ver-
sus 32% and 3-year 17% versus 25% log rank p  0.80)
chemoradiation for limited stage SCLC (2-year overall sur-
vival 50% versus 34% 3-year 25% versus 23% log rank p 
0.80), or palliative chemotherapy (1-year overall survival
25% versus 24% log rank p  0.50). The latter three are
reassuring because despite more patients receiving these
treatments, a similar proportion benefited.
There was a slight decline in the median survival of
patients undergoing palliative radiotherapy (5.2 to 4.4 months
log rank p  0.009), probably reflecting changes in patient
selection. In 2002, palliative radiotherapy was delivered to
patients unsuitable for either radical radiotherapy or palliative
chemotherapy.
Relative Survival
An alternative explanation for the observed improve-
ment in survival is the trend for increasing life expectancy in
Scotland. Therefore to exclude this as a reason, the relative
survival was calculated which estimates expected survival
from nationwide population life tables stratified by age, sex,
and calendar time. Relative survival estimates were produced
using the methodology described by Dickman et al.9 The
standard error of the cumulative relative survivals were cal-
culated using the Ederer method.10
This analysis demonstrated that there were significantly
more patients alive at 12 months after diagnosis with a
relative survival of 30.6% in 2002 compared with 24.7% in
1995 (p  0.005). The difference in relative survival at 24
months after diagnosis was also found to be significant
(16.4% versus 12.4% p  0.02). The relative survival at 3
years was not statistically significantly different, but the
numbers of patients included in the analysis at this time point
was small (106 and 143) (Table 5).
DISCUSSION
Over recent years, population-based cancer survival for
a number of tumors, such as colorectal and breast cancers
have shown a gratifying improvement.11 Unfortunately, de-
spite improvements in surgery, radiotherapy and chemother-
apy population-based survival for lung cancer patients has
changed very little.2,3,12




Surgery only 82 (15%) 78 (14%)
Surgery and post-operative radiotherapy 7 (1%) 19 (3%)
Surgery and chemotherapy 1 (0.2%) 2 (0.3)
Surgery and palliative radiotherapy 2 (0.4%) 2 (0.3%)
Radical radiotherapy 18 (3.3%) 50 (8.7%)
Radical radiotherapy and chemotherapy 1 (0.2%) 27 (4.7%)
Palliative radiotherapy 219 (40.5%) 174 (30.4%)
Palliative radiotherapy and chemotherapy 20 (4%) 32 (5.6%)
Chemotherapy 17 (3%) 39 (6.8%)
None 176 (32.4%) 149 (26%)
SCLC
Surgery and chemotherapy /RT 1 (0.5%) 1 (0.5%)
Chemotherapy and adjuvant radiotherapy 12 (7%) 26 (18%)
Palliative radiotherapy 17 (10%) 10 (7%)
Palliative radiotherapy and chemotherapy 19 (11.5%) 17 (12%)
Chemotherapy 78 (46%) 52 (37%)
None 39 (23%) 35 (25%)
No pathology
Radical radiotherapy 5 (2%) 24 (9%)
Palliative radiotherapy 79 (38%) 52 (20%)
None 130 (60%) 182 (71%)
Bold, potentially curative treatment; Italics, palliative; %, percentage of patholog-
ical group.
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; RT, radiotherapy.
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Lung cancer survival in Scotland, and the United King-
dom as a whole,2 is lower than that reported in many Euro-
pean countries, Australia, and North America.3,13–21 The
reasons for this inferior outcome are complex, but relate to
differences in data collection and reporting, patient and tumor
characteristics, and treatment.22
The methodology used in this study, including hospital
and community diagnosed patients, and both pathologically
confirmed and radiology-only diagnosed cases, ensures that
the management and survival described reflects the true
population-based figures. Many studies are restricted to only
a subset of patients or do not include nonpathologically
confirmed cases.8 As shown in this study, exclusion of this
latter group can have a major impact on outcome (median
survival of 4.6 months when patients with a radiology-only
diagnosis are included versus 5.6 months when these cases
are excluded). The two cohorts were recorded and analyzed
in a similar manner to ensure, as closely as possible, a valid
comparison. The higher case ascertainment in the later cohort
would, if anything, have resulted in the identification of older
FIGURE 1. Comparison of lung cancer survival in South-
East Scotland 1995 versus 2002.
















Male 681 (63%) 0.42 1 1 207 (19%) 0.72 1 1
Female 506 (62%) 0.9 (0.8–1.1) 0.9 (0.7–1.1) 153 (19%) 1.0 (0.8–1.2) 0.9 (0.7–1.2)
60 223 (84%) 0.001 1 1 85 (32%) 0.001 1 1
60–69 406 (75%) 0.6 (0.4–0.8) 0.7 (0.4–0.99) 137 (25%) 0.7 (0.5–0.99) 0.6 (0.4–0.9)
70–79 457 (59% 0.3 (0.2–0.4) 0.4 (0.2–0.5) 119 (16%) 0.4 (0.3–0.5) 0.3 (0.2–0.4)
80 101 (32%) 0.1 (0.06–0.13) 0.1 (0.08–0.2) 19 (6%) 0.1 (0.08–0.2) 0.1 (0.03–0.12)
Carstairs
1 176 (63%) 0.76 1 1 66 (24%) 0.33 1 1
2 214 (65%) 1.0 (0.8–1.5) 1.0 (0.7–1.5) 60 (18%) 0.7 (90.5–1.1) 0.7 (0.4–1.1)
3 287 (63%) 1.0 (0.7–1.4) 0.9 (0.6–1.3) 84 (18%) 0.7 (0.5–1.1) 0.7 (0.4–1.1)
4 347 (61%) 0.9 (0.7–1.2) 0.9 (0.6–1.3) 103 (18%) 0.4 (0.5–1.0) 0.6 (0.4–1.04)
5 148 (63%) 1.0 (0.7–1.5) 1.0 (0.6–1.5) 47 (20%) 0.8 (0.5–1.2) 0.6 (0.3–1.04)
Lothian 835 (65% 0.001 1 1 272 (21%) 0.001 1 1
Borders 95 (67%) 1.1 (0.8–1.6) 1.2 (0.8–2.0) 25 (18%) 0.8 (0.5–1.3) 0.6 (0.3–1.1)
Fife 257 (55%) 0.7 (0.5–0.8) 0.7 (0.5–0.9) 63 (13%) 0.6 (0.4–0.8) 0.5 (0.3–0.7)
NSCLC 790 (71%) 0.001 1 1 289 (26%) 0.001 1 1
SCLC 235 (76%) 1.3 (1.0–1.7) 1.8 (1.3–2.5) 42 (14%) 0.5 (0.3–0.6) 1.3 (0.8–2.1)
No path 162 (34%) 0.2 (0.1–0.3) 0.3 (0.2–0.4) 29 (6%) 0.2 (0.1–0.3) 0.2 (0.1–0.4)
Localized 272 (75%) 0.001 1 1 165 (45%) 0.001 1 1
Regional 485 (74%) 0.9 (0.7–1.3) 0.7 (0.5–0.99) 188 (29%) 0.5 (0.4–0.6) 0.2 (0.16–0.3)
Metastatic 397 (58%) 0.4 (0.3–0.6) 0.3 (0.2–0.5) 8 (1%) 0.01 (0–0.03) 0.004 (0–0.009)
Unknown 33 (17%) 0.07 (0.–0.1) 0.1 (0.05–0.1) 0 — —
1995 582 (63%) 0.83 1 1 131 (14%) 0.001 1 1
2002 605 (62%) 1.0 (0.8–1.2) 1.3 (1.06–1.7) 229 (24%) 1.9 (1.5–2.4) 6.0 (4.3–8.5)
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
TABLE 4. Overall Survival in South-East Scotland 1995 vs. 2002
Median 1 yr 2 yr 3 yr Log Rank
1995 (n  927) 4.1 (3.5–4.6) 23.4% (20.7–26.1) 11.4% (9.3–13.5) 8.3 (6.5–10.0) 0.004
2002 (n  971) 5.2 (4.5–5.8) 29.1% (26.3–31.9) 14.8% (12.7–17.2) 10.5 (8.6–12.7)
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patients, with more advanced disease who were less likely to
receive treatment.
Over the 7-year period, the median age of the popula-
tion increased from 70 to 72 years. This trend will continue as
the Scottish birth cohorts with the highest lung cancer risk
become older.23 This will present an increasing challenge to
lung cancer specialists as the majority of cancer therapies, but
particularly surgery,24–26 are more difficult to deliver to
elderly patients. This aging trend is seen in most other
Western countries with most recent series reporting median
(or mean) ages of 65 to 70 years.14,15,19,21,27 The other patient
characteristics, such as sex and deprivation did not change,
though more patients in the later cohort came from Fife. As
the Scottish Cancer Registry had not recorded a similar
change this was probably a consequence of improved case-
ascertainment, rather than changes in incidence in Fife.
There was no statistical difference in the pathologic
types of lung cancer, but there was an apparent increase in the
proportion of patients presenting with metastatic disease. It
seems unlikely that this is genuine, but is more likely to
reflect (i) the higher case ascertainment, (ii) greater use of CT
scanning, and (iii) technical improvements in CT scanning
and more experienced radiologists resulting in higher detec-
tion of metastatic deposits. Positron emission tomography scans
were not routinely available in South-East Scotland in 2002.
The proportion of 42% of patients in 2002 presenting
with distant disease is similar to that seen in many popula-
tion-based series, though 14% of cases with localized disease
is a little lower. Most recent series report around 20% of
patients with localized disease.14–19,21,28 The lower proportion
of patients with early stage cancers will inevitably impact on
long-term survival figures.
Treatment
The crude rate of use of treatment did not increase over
time, with 38% of lung cancer patients not receiving any form
of therapy. “No-treatment” rates vary greatly around the
world; from 85% of patients in some areas of South-East
England29 to 28% in New South Wales.21 The optimal use of
treatment in any one population will vary depending on the
patients’ and tumors’ suitability for treatment. A population
with a fit population presenting with more localized disease
will, in general, be more suitable for treatment. Scotland has
one of the highest rates of cardiovascular disease in the
world,30 which makes surgery and platinum-based chemo-
therapy more hazardous.
Although the use of treatment overall did not increase,
the use of “PCT” nearly doubled. This was not because of an
increase in surgery, which remained static at just over 10% of
the population, however, the use of potentially curative ra-
diotherapy trebled. The resection rate is much lower than
most international series which report rates of 19% to
26%,14,18,19,21,28 but similar to other UK and Irish se-
ries.27,29,31 The lack improved resection rates is likely to be
because of the low proportion of patients presenting with
early stage disease and high prevalence of comorbid disease.
The population-based use of radical radiotherapy was
15% is high, but there are few data to compare as few other
population-based series report radiotherapy intent. In a com-
panion study, a cohort of patients diagnosed in British Co-
lumbia in 1995 of 2073 patients, 3.7% received radical
radiotherapy (unpublished data Erridge et al.). In a Dutch
series of 807 patients with NSCLC 15%), patients with Stage
I–II and 30% patients with Stage IIIA disease received radical
radiotherapy. This compares with 30% and 22%, respec-
tively, in South-East Scotland in 2002.
Although there was an increase in use of radical radio-
therapy across the region, there were significant variations
between the three health boards. The causes of this are
unclear as the patients are managed according to the same
protocols and the rate of pathologic confirmation and CT
scanning was similar between the health boards suggesting
the variation was not was not therapeutic nihilism. The most
likely explanation is variation in levels of comorbidity, but a
prospective study on the rationale behind management
choices is required to understand the variation in management
across the region more fully.
While the use of potentially curative radiotherapy in-
creased, the use of radiotherapy in general did not. The
population-based rate of radiotherapy in the first 6 months
after diagnosis remained at around 45%. This rate is similar
to other studies that include nonpathologically confirmed
cases,19,27,31–33 but a little lower than in SEER series.14,17,34
Models estimating the optimal use of radiotherapy in Canada35
and Australia36 suggested between 61% and 76% of lung
cancer patients should receive this treatment during their
illness. A benchmarking study in Canada suggested that
around 41% might be more appropriate rate.34 Over recent
years, the use of palliative radiotherapy actually reduced in
South-East Scotland (41% versus 29%). This is probably be-
cause of increased use of radical radiotherapy and also palliative
chemotherapy that confers a survival benefit not seen with
low-dose palliative radiotherapy. A similar trend has also been
seen in the Netherlands33 and the United States.37
The use of chemotherapy for NSCLC increased from
7% to 18%. This follows the publication of evidence on the
survival benefit, without cost to quality of life, in patients
with metastatic disease38 and in combination with radical
radiotherapy.39 The data on the role of adjuvant postoperative
chemotherapy was not available in 2002 so this was not in
routine use at this time. The increase in use of chemotherapy
TABLE 5. Relative Survival in South-East Scotland 1995 vs. 2002
1 yr Since Diagnosis 2 yr Since Diagnosis 3 yr Since Diagnosis
1995 n  927 24.7% (21.8–27.6) n  218 12.4 (10.3–14.8) n  106 9.3 (7.5–11.4)
2002 n  971 30.6% (27.7–33.7) n  278 16.4 (14.0–19.0) n  143 12.0 (9.9–14.3)
2002 vs. 1995 p  0.005 p  0.020 p  0.077
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in metastatic disease will have a moderate impact on median
and 1-year survival, but little impact on 2-year survival.
The use of chemotherapy in NSCLC in 2002 is similar
to that seen in most series from the late 1990s,21,27,32 and one
English series, which includes patients from 200240, though it
is difficult to establish the use in United States as SEER does
not collect data on chemotherapy. Consequently, these data
are only available for the United States from Medicare for
patients over 65 years of age.41
The use of chemotherapy for SCLC in South-East
Scotland remained relatively stable (65% versus 68%), but a
little lower than in other countries where the rates of chemo-
therapy use range from 73% to 92% of patients with
SCLC,21,32,42 however, the rate in South-East Scotland was
higher than in South-East England (50%) in the same peri-
od.40 There was an increase in the proportion of SCLC
patients receiving chemo-radiation from 7% to 18%. This
will increase the number of long-term survivors slightly, but
limited stage SCLC patients constitute only around 6% of the
whole lung cancer population. Consequently, a survival rate
of 40% at 2 years and 20% at 5 years43 translates to around
a 2.4% and 1.2% increase in population-based survival,
respectively.
Survival
The overall survival and relative survival of lung cancer
patients in South-East Scotland improved over the period
from 1995 to 2002. Although the median survival only
increased by 1 month, the absolute increase at 2 years was
4.8%, which represents nearly a 50% improvement. There are
very few reports of improved population-based survival for
lung cancer patients. Gadgeel et al.17 reported improved
survival in Detroit over the period 1973–1993 for white, but
not black patients and Lebitasy et al. reported improved
survival for patients with SCLC over the period 1981–1994,
but no improvement was seen in patients with NSCLC from
the same region.42,44 A recent analysis of the outcome of lung
cancer patients in Sweden over the last 40 years demonstrated
an improvement in the 1-year relative survival for patients
with adenocarcinoma and squamous cell tumors, but no
improvement was seen after 5 years.45 Several other studies
have been unable to identify an improvement.2,3,12
The changes in patient and tumor characteristics would,
if anything, have a detrimental impact on outcome. Increased
lead-time due to earlier diagnosis could be contributory, but
this is unlikely because the outcome after specific treatments
was unchanged.
The increased use of treatment, particularly the in-
creased use of radical radiotherapy, is likely to be contribu-
tory to the improved survival. Over the period 1995 to 2002,
new radiotherapy techniques and greater experience of the
oncologists enabled patients with bulky tumors or poor pul-
monary function to be offered this treatment. As the number
of patients receiving treatment, particularly radiotherapy, has
not increased it appears the increased use of radical radio-
therapy is primarily because of a change in approach of the
oncologists rather than an effect of the wider changes in the
structure of the lung cancer service. The role of the introduc-
tion of multidisciplinary meetings in the change of manage-
ment is difficult to establish; one would have expected the
proportion of patients treated to increase had this had a major
impact. The development of team-based management of pa-
tients by the lung cancer oncologists may have provided the
supportive and educational environment to enable the change in
radiotherapy intent and increased use of chemotherapy.
Nevertheless, when the variable “treatment intent” was
included in the Cox’s proportional hazards model, the hazard of
death in 2002 remained significantly reduced suggesting that
other uncharacterized factors not collected in this study, such as
comorbidity and patient choice might also be important.
CONCLUSIONS
There has been a demonstrable improvement in the
duration of survival of lung cancer patients in South-East
Scotland. This appears to be due at least in part to more
patients receiving radical radiotherapy, and to a lesser extent
chemo-radiation for limited stage SCLC and palliative che-
motherapy for NSCLC.
Although the rates of treatment and survival have
increased, there are still variations in treatment within the
region. The reasons for this are as yet unclear, however, there
is a view that this maybe related to regional variations in
levels of co morbid disease. A prospective study on the
rationale behind management choices is required to under-
stand the variation in management across the region.
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